• Publications
  • Influence
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
TLDR
Treatment failure and CNS side-effects are associated with low and high efavirenz plasma levels, respectively, which strongly argues for dose adjustment on the basis of therapeutic drug monitoring to optimize treatment.
Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals
TLDR
CYP2B6 poor metabolizer genotypes explain to a large extent EFV pharmacokinetics and identify individuals at risk of extremely elevated EFV plasma levels.
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
TLDR
CYP2B6 genotyping may be useful to complement an individualization strategy based on plasma drug determinations to increase the safety and tolerability of EFV.
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
TLDR
This is the first human pharmacokinetic study on TMZ to quantify CSF penetration and systemic or cerebral exposures are not better predictors than the cumulative dose alone for both efficacy and safety.
Towards a new combination therapy for tuberculosis with next generation benzothiazinones
TLDR
Compared to BTZ043, PBTZ169 has improved potency, safety and efficacy in zebrafish and mouse models of tuberculosis (TB), and when combined with other TB drugs, it showed additive activity against M. tuberculosis in vitro except with bedaquiline (BDQ) where synergy was observed.
Diet Acids and Alkalis Influence Calcium Retention in Bone
TLDR
It is confirmed that renally excreted acids derived from food influence calcium metabolism, and that alkalizing nutrients inhibit bone resorption, and further studies are needed to determine the clinical impact of dietary counseling for avoiding diet acids as a preventive measure against osteoporosis.
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
TLDR
Several pharmacokinetic aspects yet remain insufficiently investigated for imatinib mesylate, dasatinib, and nilotinib and widely prescribed co-medications, including known inhibitors or inducers of cytochrome P450 or drug transporters are reviewed.
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
TLDR
The efavirenz pharmacokinetic profile and interpatient versus intrapatient variability in patients who are positive for human immunodeficiency virus is assessed to explore the relationship between drug exposure, efficacy, and central nervous system toxicity and to build up a Bayesian approach for dosage adaptation.
Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania
TLDR
The observed reduction in the relative bioavailability of lumefantrine in pregnant women may explain the higher treatment failure in this group, mostly due to lower posttreatment prophylaxis.
Population pharmacokinetics of imatinib and the role of α1-acid glycoprotein
TLDR
Because of the high pharmacokinetic variability of imatinib and the reported relationships between its plasma concentration and efficacy and toxicity, the usefulness of therapeutic drug monitoring as an aid to optimizing therapy should be further investigated.
...
...